

**Remarks/Arguments**

Reconsideration of this application is respectfully requested, in view of the following remarks.

Claims 1, 3, 6, 7, 10-12 and 14-18 are pending. Claim 14 is amended to correct a misspelling .

In the Office Action mailed July 11, 1007, the Examiner has required restriction between the following claim groups:

Group I: Claims 3 and 14-16, which cover methods of treating diseases or disorders, Including Parkinson's Disease, dyskinesia, tardive dyskinesia, Huntington's disease, tremor, chorea, myoclonus, tick disorder, akinetic rigid syndrome, bradykinesia, dystonia, etc.

Group II: Claims 6-10, 12, covering a combination with an agent selected from levodopa, levodopa with a selective extracerebral decarboxylase inhibitor, carbidopa, entacapone, anticholinergic, a COMT inhibitor, an A2a adenosine receptor antagonista, a cholinergic agonist, a dopamine agonist, a butyrophenon neuroleptic agent, etc.


Group III: Claim 7, covering acetophenazine, alentemol, benzhexol, bromocriptine, biperiden, etc.

The Examiner has also required election of a single species from each group, in the event that no generic claim is allowable.

In response, applicants elect the Group I claims, without traverse. Applicants elect Parkinson's Disease as the preferred disease or disorder in Group I. Claims 3 and 14 read on the elected species.

Favorable action is earnestly solicited.

Respectfully submitted,

By   
John C. Todaro, Reg. No. 36,036  
Attorney for Applicants

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065  
Tel.: (732) 594-0125

Date: August 9, 2007